Bristol-Myers Squibb Co vs Main Street Capital Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.5 (market cap $129.94B), while Main Street Capital Corporation trades at $59 (market cap $5.52B). The key difference: Bristol-Myers Squibb Co is far larger — about 23.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.39%). Which is the better fit depends on your goals.
| BMY | MAIN | |
|---|---|---|
Market Cap | $129.94B | $5.52B |
Sector | Health | Financials |
52-Week High | $65.89 | $67.54 |
52-Week Low | $42.60 | $49.63 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 5.39% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →